Recurrent uveitic macular edema managed with intravitreal faricimab injection

Area of Science:

• Ophthalmology
• Immunology

Background:

• Uveitic macular edema (UME) poses a significant challenge in managing inflammatory eye conditions.
• Birdshot chorioretinopathy (BSCR) is a chronic inflammatory disease that frequently leads to recurrent UME.
• Previous treatments for UME in BSCR often yield limited success and can cause intolerance.

Purpose of the Study:

• To report a case of recurrent uveitic macular edema (UME) successfully treated with intravitreal faricimab.
• To evaluate the efficacy of faricimab in a patient with treatment-resistant UME secondary to birdshot chorioretinopathy.

Main Methods:

• A single case report from a tertiary referral center.
• A 63-year-old female with recurrent UME due to BSCR received one dose of intravitreal faricimab.
• Optical coherence tomography (OCT) was used to monitor macular edema and subretinal fluid.

Main Results:

• The patient presented with recurrent UME and subretinal fluid despite multiple prior treatments.
• Following a single intravitreal faricimab injection, complete resolution of UME was achieved.
• The therapeutic effect was maintained for at least three months post-injection.

Conclusions:

• Intravitreal faricimab demonstrated significant efficacy in resolving treatment-resistant uveitic macular edema.
• Faricimab's dual action on angiopoietin-2 and VEGF-A may contribute to its effectiveness in UME.
• Further research is warranted to confirm the role of faricimab in managing UME.